Ten-Patient Trial: Remarkable Responses in Pediatric Cancers.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 37733329.
- Also identified by DOI 10.1158/1078-0432.CCR-23-2232 and PMC identifier 10690083.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A clinical trial of nivolumab in 10 patients with pediatric cancer with high tumor mutational burden demonstrated complete responses in 50% of patients. This result recapitulates multiple clinical trial results in high mutation-burden adult cancers and may redefine best practice in the setting of germline DNA mismatch repair-based susceptibility. See related article by Das et al., p. 4770.
Medical subject headings
- Nivolumab
- Neoplasms